CA3195291A1 — Preservative-free ophthalmic pharmaceutical emulsion and its application
Assigned to Caravel Therapeutics Inc · Expires 2023-10-13 · 3y expired
What this patent protects
The present invention provides a preservative-free ophthalmic pharmaceutical emulsion containing a nitric oxide-donating prostaglandin F2a derivative or a pharmaceutically acceptable salts or esters thereof as an active ingredient. The present invention also provides its applicat…
USPTO Abstract
The present invention provides a preservative-free ophthalmic pharmaceutical emulsion containing a nitric oxide-donating prostaglandin F2a derivative or a pharmaceutically acceptable salts or esters thereof as an active ingredient. The present invention also provides its application of promoting blood velocity of optic nerve head (ONH) for treating glaucoma patients and lowering risks for open angle glaucoma and retinal ischemia disease, such as retinal vein occlusion (RVO), including central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), and retinal artery occlusion (RAO), including central retinal artery occlusion (CRAO) and branch retinal artery occlusion (BRAO).
Drugs covered by this patent
- Vyzulta (LATANOPROSTENE BUNOD) · Bausch Health
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.